Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit Insights From the DANISH Trial

被引:43
|
作者
Kristensen, Soren Lund [1 ,2 ]
Levy, Wayne C. [3 ]
Shadman, Ramin [4 ]
Nielsen, Jens C. [5 ]
Haarbo, Jens [6 ]
Videbaek, Lars [7 ]
Bruun, Niels E. [8 ,9 ,10 ]
Eiskjaer, Hans [5 ]
Wiggers, Henrik [5 ]
Brandes, Axel [7 ]
Thogersen, Anna Margrethe [11 ]
Hassager, Christian [1 ,12 ]
Svendsen, Jesper H. [1 ,12 ]
Hofsten, Dan E. [1 ]
Torp-Pedersen, Christian [11 ]
Pehrson, Steen [1 ]
Signorovitch, James [13 ]
Kober, Lars [1 ,12 ]
Thune, Jens Jakob [2 ,12 ]
机构
[1] Copenhagen Univ Hosp, Dept Cardiol, Rigshosp, Copenhagen, Denmark
[2] Bispebjerg Hosp, Dept Cardiol, Copenhagen, Denmark
[3] Univ Washington, Seattle, WA 98195 USA
[4] Southern Calif Permanente Med Grp, Los Angeles, CA USA
[5] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark
[6] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark
[7] Odense Univ Hosp, Dept Cardiol, Odense, Denmark
[8] Zealand Univ Hosp, Dept Cardiol, Roskilde, Denmark
[9] Clin Inst, Copenhagen, Denmark
[10] Aalborg Univ, Aalborg, Denmark
[11] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark
[12] Univ Copenhagen, Dept Clin Med, Fac Hlth & Med Sci, Copenhagen, Denmark
[13] Anal Grp, Boston, MA USA
关键词
implantable cardioverter-defibrillator; nonischemic cardiomyopathy; risk prediction; SEATTLE HEART-FAILURE; SUDDEN CARDIAC DEATH; PRIMARY PREVENTION; DILATED CARDIOMYOPATHY; PROPORTIONAL RISK; AMIODARONE; SURVIVAL; THERAPY;
D O I
10.1016/j.jchf.2019.03.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study aims to identify patients with nonischemic heart failure who are more likely to benefit from implantable cardioverter-defibrillator (ICD) implantation by use of established risk prediction models. BACKGROUND It has been debated whether an ICD for primary prevention reduces mortality in patients with nonischemic heart failure. METHODS The Seattle Heart Failure Model (SHFM) predicts all-cause mortality whereas the Seattle Proportional Risk Model (SPRM) predicts the proportion of sudden cardiac death (SCD) versus nonsudden death, with a higher score indicating a greater proportion of SCD. We report the effect of ICD implantation on all-cause mortality and SCD, according to median SPRM and SHFM scores in all 1,116 patients enrolled in the DANISH (Danish study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on mortality) trial. RESULTS Among patients with an SPRM score above the median (n = 558), ICD implantation reduced all-cause mortality (hazard ratio [HR]: 0.63; 95% confidence interval [CI]: 0.43 to 0.94), whereas patients with lower SPRM scores (n = 558) had no effect (HR: 1.08; 95% CI: 0.78 to 1.49, p for interaction = 0.04). The corresponding numbers for SHFM score above and below the median were HR: 0.84; 95% CI: 0.62 to 1.13 and HR: 0.82; 95% CI: 0.53 to 1.28, respectively (p for interaction = 0.980). In 177 patients with upper SPRM/upper SHFM, ICD implantation reduced all-cause mortality (HR: 0.45; 95% CI: 0.25 to 0.80) when compared to 381 patients with lower SPRM/upper SHFM (HR: 1.09; 95% CI: 0.76 to 1.55) (p for interaction < 0.001). CONCLUSIONS Nonischemic heart failure patients with high predicted relative likelihood of SCD, as estimated by higher SPRMscore, seemed to benefit from ICD implantation. (C) 2019 by the American College of Cardiology Foundation.
引用
收藏
页码:717 / 724
页数:8
相关论文
共 50 条
  • [31] Risk prediction of inappropriate implantable cardioverter-defibrillator therapy using machine learning
    Tateishi, Ryo
    Suzuki, Makoto
    Shimizu, Masato
    Shimada, Hiroshi
    Tsunoda, Takahiro
    Miyazaki, Hiroko
    Misu, Yoshiki
    Yamakami, Yosuke
    Yamaguchi, Masao
    Kato, Nobutaka
    Isshiki, Ami
    Kimura, Shigeki
    Fujii, Hiroyuki
    Nishizaki, Mitsuhiro
    Sasano, Tetsuo
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [32] Risk prediction of inappropriate implantable cardioverter-defibrillator therapy using machine learning
    Tateishi, R.
    Suzuki, M.
    Shimizu, M.
    Shimada, H.
    Tsunoda, T.
    Miyazaki, H.
    Misu, Y.
    Yamakami, Y.
    Yamaguchi, M.
    Kato, N.
    Isshiki, A.
    Kimura, S.
    Fujii, H.
    Nishizaki, M.
    Sasano, T.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [33] Risk prediction of inappropriate implantable cardioverter-defibrillator therapy using machine learning
    Ryo Tateishi
    Makoto Suzuki
    Masato Shimizu
    Hiroshi Shimada
    Takahiro Tsunoda
    Hiroko Miyazaki
    Yoshiki Misu
    Yosuke Yamakami
    Masao Yamaguchi
    Nobutaka Kato
    Ami Isshiki
    Shigeki Kimura
    Hiroyuki Fujii
    Mitsuhiro Nishizaki
    Tetsuo Sasano
    Scientific Reports, 13 (1)
  • [34] The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial
    Bundgaard, Johan S.
    Thune, Jens J.
    Nielsen, Jens C.
    Videbaek, Regitze
    Haarbo, Jens
    Bruun, Niels E.
    Videbaek, Lars
    Aagaard, David
    Korup, Eva
    Jensen, Gunnar
    Hildebrandt, Per
    Steffensen, Flemming H.
    Eiskjaer, Hans
    Brandes, Axel
    Thogersen, Anna M.
    Melchior, Thomas M.
    Pedersen, Ole D.
    Gustafsson, Finn
    Egstrup, Kenneth
    Hassager, Christian
    Svendsen, Jesper H.
    Hofsten, Dan E.
    Torp-Pedersen, Christian
    Pedersen, Susanne S.
    Pehrson, Steen
    Kober, Lars
    Mogensen, Ulrik M.
    EUROPACE, 2019, 21 (06): : 900 - 908
  • [35] Optimizing patient selection for primary prevention implantable cardioverter-defibrillator implantation: utilizing multimodal machine learning to assess risk of implantable cardioverter-defibrillator non-benefit
    Kolk, Maarten Z. H.
    Ruiperez-Campillo, Samuel
    Deb, Brototo
    Bekkers, Erik J.
    Allaart, Cornelis P.
    Rogers, Albert J.
    van der Lingen, Anne-Lotte C. J.
    Florez, Laura Alvarez
    Isgum, Ivana
    De Vos, Bob D.
    Clopton, Paul
    Wilde, Arthur A. M.
    Knops, Reinoud E.
    Narayan, Sanjiv M.
    Tjong, Fleur V. Y.
    EUROPACE, 2023, 25 (09):
  • [36] Risk of Failure of Transvenous Implantable Cardioverter-Defibrillator Leads
    Borleffs, C. Jan Willem
    van Erven, Lieselot
    van Bommel, Rutger J.
    van der Velde, Enno T.
    van der Wall, Ernst E.
    Bax, Jeroen J.
    Rosendaal, Frits R.
    Schalij, Martin J.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2009, 2 (04): : 411 - 416
  • [37] Who needs an implantable cardioverter-defibrillator? Controversies and opportunities after DANISH
    Petrie, Mark C.
    Connelly, Derek T.
    Gardner, Roy S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (03) : 413 - 416
  • [38] Statin therapy reduces the risk of shock from an implantable cardioverter-defibrillator
    Chiu, JH
    Abdelhadi, RH
    Natale, A
    Gurm, HS
    Chung, MK
    Marrouche, NF
    Saliba, WI
    Rossillo, A
    Saad, EB
    Martin, DO
    CIRCULATION, 2003, 108 (17) : 543 - 543
  • [39] Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator
    Uslu, Abdulkadir
    Dogan, Cem
    Duman, Hakan
    Tanboga, Ibrahim Halil
    Askin, Lutfu
    Sevimli, Serdar
    NORTHERN CLINICS OF ISTANBUL, 2019, 6 (01) : 40 - 47
  • [40] Successful extravascular implantable cardioverter-defibrillator implantation in a patient with recurrent transvenous implantable cardioverter-defibrillator erosion
    Robinson, Andrea
    Billakanty, Sreedhar
    Fu, Eugene
    Amin, Anish
    HEART RHYTHM O2, 2024, 5 (04): : 243 - 245